A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study (the second phase in testing a new drug or drug combination) to see
how useful adding investigational drug cediranib to olaparib after disease progression on
olaparib alone in patients with ovarian cancer.